FDA rushed out agency-wide AI tool—it’s not going well
Under the Trump administration, the Food and Drug Administration is eagerly embracing artificial intelligence tools that staff members are reportedly calling rushed, buggy, overhyped, and inaccurate.
On Monday, the FDA publicly announced the agency-wide rollout of a large language model (LLM) called Elsa, which is intended to help FDA employees—”from scientific reviewers to investigators.” The FDA said the generative AI is already being used to “accelerate clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets.”
“It can summarize adverse events to support safety profile assessments, perform faster label comparisons, and generate code to help develop databases for nonclinical applications,” the announcement promised.
Related Knowledge Center: Artificial intelligence
On top of a failing business model, newsrooms must navigate the powerful — and not fully reliable — new capabilities of artificial intelligence and the deployment of large language models.
State of the business model | Copyright and intellectual property
Related Knowledge Center: Information integrity
In an increasingly fractured media landscape, truth has been a casualty in the public discussion. Coverage has been warped by the business needs of struggling news organizations, and a significant segment of the public relies on bad-faith outlets that are little more than propagandists. While fact-checking has become routine, some organizations are exploring other ways to combat the trends. And misinformation spewed by AI-driven chatbots has become more of a feature than simply a bug.
Fact-checking and its detractors